CAN1012

Canwell Biotech Limited · Phase 1 active Small molecule

At a glance

Generic name	CAN1012
Also known as	Toripalimab
Sponsor	Canwell Biotech Limited
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CAN1012 CI brief — competitive landscape report
CAN1012 updates RSS · CI watch RSS
Canwell Biotech Limited portfolio CI